Symbols / RCKT $4.87 +2.96%

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops ex vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red de Enfermedades Raras, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Price estimates from analyst targets and simple models.

Latest analyst rating changes

• $RCKT stock is up 13% today. Here's what we see in our data. - Quiver Quantitative Mon, 09 Mar 2026 19
• Suvretta Capital Management LLC Cuts Position in Rocket Pharmaceuticals, Inc. $RCKT - MarketBeat Sat, 14 Mar 2026 12
• [EFFECT] ROCKET PHARMACEUTICALS, INC. SEC Filing - Stock Titan Wed, 11 Mar 2026 04
• Morgan Stanley Names Rocket Pharmaceuticals (RCKT) as Key Beneficiary of 2026 Biotech Sector Recovery - Yahoo Finance Wed, 18 Feb 2026 08
• Rocket Pharmaceuticals, Inc. (RCKT) Stock Analysis: Exploring A 71% Upside Potential - DirectorsTalk Interviews Sat, 28 Feb 2026 05
• Rocket Pharmaceuticals (RCKT) Launches $100 Million Stock Offeri - GuruFocus ue, 10 Mar 2026 22
• Rocket Pharmaceuticals, Inc. $RCKT Holdings Trimmed by Prosight Management LP - MarketBeat Sat, 14 Mar 2026 11
• Rocket Pharmaceuticals (RCKT) launches $100M at-the-market stock offering with Cantor - Stock Titan ue, 10 Mar 2026 21
• Rocket Pharmaceuticals (RCKT) Stock Target Reduced Following Q3 2025 Update on Cash Position - Yahoo Finance Mon, 15 Dec 2025 08
• Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Up 14.3% Following Earnings Beat - MarketBeat Fri, 27 Feb 2026 08
• Rocket Pharmaceuticals (RCKT) launches up to $100M ATM offering with Cantor - Stock Titan ue, 10 Mar 2026 21
• RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy - Yahoo Finance Wed, 15 Oct 2025 07
• Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Up 5.4% - What's Next? - MarketBeat Mon, 09 Mar 2026 17
• Gene therapy company spotlights rare-disease work at J.P. Morgan event - Stock Titan Mon, 05 Jan 2026 08
• RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus - Yahoo Finance Fri, 27 Feb 2026 08

• Income Statement
• Balance Sheet
• Cash Flow

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

• 8-K2026-03-10 View
• 8-K2026-02-26 View
• 10-K2026-02-26 View
• 42026-02-20 View
• 42026-02-20 View
• 42026-02-20 View
• 42026-02-18 View
• 42026-02-18 View
• 42026-02-18 View
• 42026-02-13 View
• 42026-02-13 View
• 42026-02-13 View
• 42026-02-13 View
• 42026-02-13 View
• 42026-02-13 View